
About Emmessar Biotech & Nutrition
Emmessar Biotech & Nutrition is a publicly listed company based in Mumbai (India) founded in 1984. Herbal healthcare and nutritional products are manufactured. The company has 14 employees. Its Indian entity Emmessar Biotech And Nutrition Ltd reported revenue of βΉ2.41 Cr. Its focus areas include Traditional Nutraceuticals and Diversified.
Company details
Founded in 1984 in Mumbai, India, operations are focused on the herbal healthcare and nutrition sector. Creams and gels are produced to address skin conditions such as burns, scars, and irritations, alongside items for muscle recovery and general skin health. Natural ingredients are utilized in formulations, with an emphasis on therapeutic applications for holistic well-being. The domain ebnl.org is maintained for online presence.
- Headquarters Mumbai, India
- Employees 14
- Stage Public
- SectorsHealthcare
- Phoneβ’β’β’β’ β’β’β’β’
- Website ebnl.org
- Legal Name Emmessar Biotech & Nutrition Ltd.
- Market Cap₹13.03 Cr
EMMESSA · BSE
- Share Price₹28.90
+10.94% today
- Revenue₹0.37 Cr
FY 2025-26 · -39.3% YoY
- EBITDA−₹1.35 Cr
Margin -364.9%
- Net Profit₹0.45 Cr
FY 2025-26 · +50.0% YoY
- P/E (TTM)30.7x
P/B 1.6x
- ROE5.6%
ROCE 6.7%
- Employee Count14
Associated legal entities of Emmessar Biotech & Nutrition
Emmessar Biotech & Nutrition operates through Emmessar Biotech And Nutrition Ltd, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Emmessar Biotech And Nutrition Ltd Listed CIN L24110MH1992PLC065942 | Active | 17 Mar 1992 | Raigad, Maharashtra | ₹2.4 Cr | 14 | 9 | View details |
Board of directors of Emmessar Biotech And Nutrition Ltd (Emmessar Biotech & Nutrition)
Emmessar Biotech And Nutrition Ltd is the primary company behind Emmessar Biotech & Nutrition. The board of Emmessar Biotech And Nutrition Ltd currently have 7 directors; the longest-serving is Srinivasa Raghavan Mathurakavi Ayyangar, appointed in 1992. 9 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Srinivasa Raghavan Mathurakavi Ayyangar DIN 00090266 | Managing Director | 17 Mar 1992 | 34 yrs 8 mo | Emmessar Biotech And Nutrition Ltd |
| Anuradha Srinivasa Raghavan DIN 06557718 | Director | 12 Aug 2013 | 13 yrs 3 mo | Emmessar Biotech And Nutrition Ltd |
| Sarada Srinivasa Raghavan DIN 06641146 | Director | 12 Aug 2013 | 13 yrs 3 mo | Emmessar Biotech And Nutrition Ltd |
| Jeyavel Balaiah Nadar DIN 08163899 | Whole-time director | 06 Feb 2021 | 5 yrs 9 mo | Emmessar Biotech And Nutrition Ltd |
| Milind Sitaram Desai DIN 00326235 | Director | 20 Oct 2022 | 4 yrs | Emmessar Biotech And Nutrition Ltd |
| Veeraraghavan Ranganathan DIN 00269682 | Director | 27 Oct 2023 | 3 yrs | Emmessar Biotech And Nutrition Ltd |
| Dinesh Kumar Deora DIN 00148325 | Director | 20 Mar 2024 | 2 yrs 7 mo | Emmessar Biotech And Nutrition Ltd |
IPO & Listings of Emmessar Biotech & Nutrition
Emmessar Biotech & Nutrition is a publicly listed company on the BSE with ticker symbol EMMESSA in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date08 Sep 2000
- Listed onBSE: 524768
- Listed entityEmmessar Biotech & Nutrition Ltd.
- Exchange sectorHealth technology
- ISININE634B01016
- Share price₹22.11 · 2026-10-14
- Market capitalisation₹11.0 Cr
- Price to earnings27.9
- EPS (diluted, trailing year)₹0.79
- Volume (last session)1,285
Financials of Emmessar Biotech & Nutrition
Exchange-reported figures of Emmessar Biotech And Nutrition Ltd, the listed company behind Emmessar Biotech & Nutrition (BSE: EMMESSA).
Financial Highlights
FY 2025-26 Β· StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 0.37 | 0.61 | 0.56 | 1.02 | 0.36 | 6.99 | 3.40 |
| Revenue growth | -39.3% | +8.9% | -45.1% | +183.3% | -94.9% | +105.6% | - |
| EBITDA | (1.35) | (0.97) | (1.08) | (0.70) | (0.91) | 0.86 | (0.67) |
| EBITDA margin | -364.9% | -159.0% | -192.9% | -68.6% | -252.8% | +12.3% | -19.7% |
| Profit before tax | 0.59 | 0.94 | 0.81 | 0.96 | 0.92 | 2.27 | 0.74 |
| Net profit | 0.45 | 0.30 | 0.75 | 0.50 | 0.47 | 1.46 | 0.97 |
| Net profit margin | +121.6% | +49.2% | +133.9% | +49.0% | +130.6% | +20.9% | +28.5% |
| EPS (βΉ) | 0.81 | 0.63 | 1.50 | 1.01 | 0.95 | 2.90 | 1.51 |
| Balance sheet | |||||||
| Total assets | 8.87 | 8.43 | 8.24 | 7.47 | 6.88 | 6.40 | 5.03 |
| Net worth | 8.12 | 7.71 | 7.41 | 6.67 | 6.17 | 5.70 | 4.27 |
| Total debt | 0.00 | 0.00 | 0.11 | 0.08 | 0.00 | 0.00 | 0.00 |
| Cash & bank | 7.32 | 6.87 | 6.18 | 5.19 | 4.58 | 2.47 | 1.88 |
| Net working capital | 7.43 | 6.91 | 6.42 | 5.59 | 4.51 | 3.99 | 2.16 |
| Cash flow | |||||||
| Cash from operations | 0.27 | 0.22 | 0.64 | 0.38 | 2.27 | 0.47 | 1.03 |
| Cash from investing | (0.26) | (0.23) | (0.64) | (0.55) | (2.61) | 0.01 | (1.06) |
| Cash from financing | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.11 | 0.06 | 0.09 | 0.09 | 0.09 | 0.09 | 0.10 | 0.10 |
| Revenue growth (YoY) | +22.2% | -33.3% | -10.0% | -10.0% | -73.5% | +12.5% | - | - |
| Other income | 0.52 | 0.54 | 0.47 | 0.49 | 0.54 | 0.53 | 0.61 | 0.43 |
| Total expenses | 0.43 | 0.41 | 0.46 | 0.43 | 0.46 | 0.37 | 0.42 | 0.38 |
| EBITDA | (0.32) | (0.35) | (0.37) | (0.34) | (0.37) | (0.28) | (0.32) | (0.28) |
| EBITDA margin | -290.9% | -583.3% | -411.1% | -377.8% | -411.1% | -311.1% | -320.0% | -280.0% |
| Depreciation | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.18 | 0.17 | 0.07 | 0.12 | 0.14 | 0.23 | 0.27 | 0.13 |
| Tax | 0.03 | 0.03 | 0.04 | 0.01 | 0.03 | 0.06 | 0.33 | 0.11 |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.11 | 0.06 | 0.09 | 0.09 | 0.09 | 0.09 | 0.10 | 0.10 |
| Revenue growth (YoY) | +22.2% | -33.3% | -10.0% | -10.0% | -73.5% | +12.5% | - | - |
| Other income | 0.52 | 0.54 | 0.47 | 0.49 | 0.54 | 0.53 | 0.61 | 0.43 |
| Total expenses | 0.43 | 0.41 | 0.46 | 0.43 | 0.46 | 0.37 | 0.42 | 0.38 |
| EBITDA | (0.32) | (0.35) | (0.37) | (0.34) | (0.37) | (0.28) | (0.32) | (0.28) |
| EBITDA margin | -290.9% | -583.3% | -411.1% | -377.8% | -411.1% | -311.1% | -320.0% | -280.0% |
| Depreciation | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.18 | 0.17 | 0.07 | 0.12 | 0.14 | 0.23 | 0.27 | 0.13 |
| Tax | 0.03 | 0.03 | 0.04 | 0.01 | 0.03 | 0.06 | 0.33 | 0.11 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.37 | 0.61 | 0.56 | 1.02 | 0.36 | 6.99 | 3.40 |
| Revenue growth | -39.3% | +8.9% | -45.1% | +183.3% | -94.9% | +105.6% | - |
| Other income | 2.04 | 2.01 | 1.99 | 1.75 | 1.92 | 1.47 | 1.47 |
| Total expenses | 1.72 | 1.58 | 1.64 | 1.72 | 1.27 | 6.13 | 4.07 |
| Employee cost | 0.00 | 0.93 | 0.96 | 0.84 | 0.77 | 0.64 | 0.58 |
| EBITDA | (1.35) | (0.97) | (1.08) | (0.70) | (0.91) | 0.86 | (0.67) |
| EBITDA margin | -364.9% | -159.0% | -192.9% | -68.6% | -252.8% | +12.3% | -19.7% |
| Depreciation | 0.10 | 0.10 | 0.10 | 0.09 | 0.09 | 0.06 | 0.06 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.59 | 0.94 | 0.81 | 0.96 | 0.92 | 2.27 | 0.74 |
| Tax | 0.14 | 0.64 | 0.06 | 0.46 | 0.45 | 0.81 | (0.02) |
| Net profit | 0.45 | 0.30 | 0.75 | 0.50 | 0.47 | 1.46 | 0.97 |
| Net profit margin | +121.6% | +49.2% | +133.9% | +49.0% | +130.6% | +20.9% | +28.5% |
| EPS (βΉ) | 0.81 | 0.63 | 1.50 | 1.01 | 0.95 | 2.90 | 1.51 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Reserves & surplus | 3.12 | 2.71 | 2.41 | 1.67 | 1.17 | 0.70 | (0.73) |
| Shareholders' funds (net worth) | 8.12 | 7.71 | 7.41 | 6.67 | 6.17 | 5.70 | 4.27 |
| Secured loans | 0.00 | 0.00 | 0.11 | 0.08 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total debt | 0.00 | 0.00 | 0.11 | 0.08 | 0.00 | 0.00 | 0.00 |
| Total liabilities | 8.87 | 8.43 | 8.24 | 7.47 | 6.88 | 6.40 | 5.03 |
| Assets | |||||||
| Gross block | 2.94 | 2.93 | 2.93 | 2.93 | 2.91 | 2.60 | 2.60 |
| Net block | 1.72 | 1.81 | 1.90 | 2.00 | 2.08 | 1.86 | 1.92 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Inventories | 0.10 | 0.12 | 0.09 | 0.14 | 0.07 | 0.07 | 1.15 |
| Sundry debtors | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | 2.71 | 0.03 |
| Cash & bank balances | 7.32 | 6.87 | 6.18 | 5.19 | 4.58 | 2.47 | 1.88 |
| Loans & advances | 0.62 | 0.58 | 0.53 | 0.59 | 0.19 | 0.14 | 0.20 |
| Total current assets | 8.06 | 7.59 | 6.82 | 5.93 | 4.85 | 5.39 | 3.26 |
| Total current liabilities | 0.63 | 0.68 | 0.40 | 0.34 | 0.34 | 1.40 | 1.10 |
| Net working capital | 7.43 | 6.91 | 6.42 | 5.59 | 4.51 | 3.99 | 2.16 |
| Total assets | 8.87 | 8.43 | 8.24 | 7.47 | 6.88 | 6.40 | 5.03 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.01 | 0.01 | 0.01 | 0.18 | 0.53 | 0.05 | 0.08 |
| Net cash from operating activities | 0.27 | 0.22 | 0.64 | 0.38 | 2.27 | 0.47 | 1.03 |
| Net cash from investing activities | (0.26) | (0.23) | (0.64) | (0.55) | (2.61) | 0.01 | (1.06) |
| Net cash from financing activities | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net change in cash | 0.02 | 0.00 | 0.00 | (0.17) | (0.34) | 0.48 | (0.03) |
| Closing cash | 7.32 | 6.87 | 6.18 | 5.19 | 4.58 | 2.47 | 1.88 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -39.3% | +8.9% | -45.1% | +183.3% | -94.9% | +105.6% | - |
| EBITDA growth | -39.2% | +10.2% | -54.3% | +23.1% | -205.8% | +228.4% | - |
| PBT growth | -39.4% | +16.1% | -15.6% | +4.4% | -59.5% | +206.8% | +164.3% |
| Net income growth | +50.0% | -60.0% | +50.0% | +6.4% | -67.8% | +50.5% | - |
| Revenue CAGR (3Y) | -28.7% | +19.2% | -56.9% | -33.1% | -17.0% | +76.6% | +9.2% |
| EBITDA CAGR (3Y) | +25.1% | +2.2% | - | +1.5% | -1.1% | - | - |
| Profitability & leverage | |||||||
| Net income margin | +116.2% | +49.2% | +133.9% | +49.0% | +130.6% | +20.9% | +22.4% |
| Return on capital employed | +6.7% | +11.5% | +10.3% | +13.4% | +14.2% | +37.1% | +17.1% |
| Return on net worth | +5.6% | +4.2% | +10.7% | +7.8% | +8.1% | +27.2% | +19.3% |
| Debt / equity | 0.00 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.01 |
| Long-term debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.13 | 0.21 | 0.19 | 0.35 | 0.13 | 2.69 | 1.30 |
| Inventory turnover | 3.36 | 5.81 | 4.87 | 9.71 | 5.14 | 11.46 | 3.62 |
| Debtors turnover | 18.50 | 30.50 | 37.33 | 102.00 | 0.26 | 5.10 | 97.14 |
| EPS (βΉ) | 0.87 | 0.63 | 1.50 | 1.01 | 0.95 | 2.90 | 1.51 |
| Dividend per share (βΉ) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (βΉ) | 16.24 | 15.43 | 14.82 | 13.34 | 12.35 | 11.41 | 8.53 |
Web traffic of Emmessar Biotech & Nutrition
The website of Emmessar Biotech & Nutrition (ebnl.org) receives about 1.6K visits a month.
- Monthly visits1.6K
▼ 3.4% vs previous month
Top companies in Traditional Health & Nutrition
3 companies that operate in the same segment as Emmessar Biotech & Nutrition (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Oral solid drug delivery systems are manufactured and developed. | 1985 | Mumbai, Maharashtra, India | USD 42.49 M | USD 72.52 M | 1,115 | |
Generic, semi-solid, and liquid dosage forms are manufactured. | 1990 | Bengaluru, Karnataka, India | USD 508.93 M | 4,050 | ||
Specialty generic pharmaceuticals and APIs are manufactured and marketed. | 1983 | Mumbai, Maharashtra, India | USD 6.44 B | 19,801 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Emmessar Biotech & Nutrition
Complete news archive for Emmessar Biotech Nutrition
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Emmessar Biotech & Nutrition
Emmessar Biotech & Nutrition was founded in 1984.
Emmessar Biotech & Nutrition is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
Emmessar Biotech & Nutrition has 14 employees.
The primary company behind Emmessar Biotech & Nutrition, Emmessar Biotech And Nutrition Ltd, reported revenue of βΉ2.41 Cr for FY 2026, down 39% year on year.
Founded in 1984 in Mumbai, India, operations are focused on the herbal healthcare and nutrition sector. Creams and gels are produced to address skin conditions such as burns, scars, and irritations, alongside items for muscle recovery and general skin health. Natural ingredients are utilized in formulations, with an emphasis on therapeutic applications for holistic well-being. The domain ebnl.org is maintained for online presence.
Yes, Emmessar Biotech & Nutrition is publicly traded on BSE under the ticker symbol EMMESSA.
Emmessar Biotech & Nutrition operates through Emmessar Biotech And Nutrition Ltd.
The legal entities of Emmessar Biotech & Nutrition currently have 8 directors, including Anuradha Srinivasa Raghavan, Sarada Srinivasa Raghavan, Jeyavel Balaiah Nadar and others.
